monoclon
antibodi
mab
gain
import
place
therapeut
arsen
sever
human
diseas
mab
approv
review
human
use
sever
hundr
current
test
treat
patient
suffer
varieti
cancer
inflammatori
diseas
concern
antivir
mab
one
direct
respiratori
syncyti
viru
rsv
approv
prophylact
treatment
pediatr
infect
howev
employ
mab
antivir
drug
consider
treatment
sever
chronic
acut
sever
viral
infect
especi
address
public
health
emerg
recent
ebola
viru
middl
east
respiratori
syndrom
coronaviru
illustr
trend
number
antivir
mab
develop
test
preclin
clinic
trial
grown
exponenti
past
year
includ
mab
direct
lifethreaten
agent
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
influenza
viru
dengu
viru
ebola
viru
sever
acut
respiratori
syndrom
viru
coronaviru
among
importantli
recent
clinic
data
also
demonstr
efficaci
antihiv
mab
control
viremia
administ
hivinfect
patient
lend
strong
support
idea
mab
could
broaden
therapeut
arsen
sever
viral
use
antivir
agent
like
consid
given
multipl
biolog
activ
may
account
therapeut
effect
although
mab
develop
inhibit
recognit
viral
receptor
coreceptor
surfac
target
cell
antivir
mab
select
abil
neutral
virion
bind
antigenbind
fab
fragment
viral
surfac
antigen
essenti
entri
host
cell
howev
biolog
activ
antibodi
also
mediat
fragment
crystalliz
region
fc
moieti
thu
interest
note
antivir
mab
use
immunoglobulin
ig
gs
display
varieti
effector
function
includ
bind
complement
receptor
differ
type
express
regul
manner
mani
cell
immun
system
includ
b
cell
natur
killer
cell
dendrit
cell
dc
monocytesmacrophag
granulocyt
mast
cell
engag
fc
antibodi
moieti
essenti
regul
antibodi
effector
upon
recognit
target
antigen
antivir
mab
facilit
viru
elimin
via
two
type
complementmedi
mechan
inactiv
viral
particl
andor
phagocytosi
opson
viru
mediat
cell
innat
immun
system
figur
ii
opson
subsequ
lysi
infect
cell
viral
antigen
also
express
cell
surfac
exampl
envelop
env
glycoprotein
lentivirus
hiv
via
complementdepend
cytotox
addit
complementmedi
action
recognit
entail
antibodydepend
cellular
phagocytosi
antibodydepend
cellmedi
cytotox
figur
final
antivir
mab
also
role
viral
blunt
inhibit
celltocel
viral
addit
control
viral
propag
mechan
opson
viral
particl
andor
infect
cell
therapeut
antivir
mab
igg
type
lead
format
immun
complex
ic
recogniz
express
antigenpres
cell
apc
dc
potenti
affect
endogen
antivir
adapt
immun
respons
passiv
immunotherapytr
individu
despit
fact
immunoregulatori
function
antibodi
well
ic
known
long
time
report
differ
experiment
set
physiopatholog
immunomodulatori
role
mab
clinic
potenti
antivir
drug
recent
consid
review
mainli
focus
induct
antivir
immun
respons
ic
passiv
immunotherapi
vaccin
strategi
potenti
deleteri
effect
antivir
antibodi
host
immun
dysfunct
andor
viral
propag
also
discuss
recent
studi
address
whether
passiv
immunotherapi
util
antivir
mab
abl
enhanc
antivir
immun
infect
individu
larg
due
limit
avail
suitabl
immunocompet
anim
model
viral
infect
allow
indepth
investig
endogen
immun
respons
concept
passiv
immunotherapi
util
antivir
mab
induc
longterm
protect
immun
recent
establish
use
immunocompet
mous
model
consist
short
immunotherapi
given
young
anim
infect
frcase
murin
leukemia
viru
induct
vaccinelik
effect
antivir
mab
well
mechan
involv
review
detail
brief
inocul
mous
pup
frcase
fatal
antivir
immun
respons
weak
control
viral
propag
contrast
treatment
neutral
mab
sever
day
shortli
infect
blunt
viral
propag
induc
lifelong
protect
antivir
immun
compos
highli
neutral
humor
respons
cytotox
tcell
induct
protect
immun
strictli
depend
fc
fragment
neutral
moreov
format
ic
compos
administ
mab
infect
cell
rather
virion
crucial
enhanc
antivir
immun
ic
recogn
express
dc
facilit
ic
intern
lead
stronger
activ
effici
antigen
present
dc
eventu
lead
stronger
cytotox
tlymphocyt
ctl
respons
fcmediat
effect
occur
concurr
inhibit
regulatori
tcell
treg
expans
depend
mab
effector
occur
rapidli
moreov
necessari
develop
protect
humor
cellular
respons
tregmedi
immunosuppress
observ
case
chronic
viral
infect
dampen
antivir
immun
respons
therebi
permit
establish
chronic
final
breastfeed
placent
transfer
matern
antifrcas
ig
induc
mab
immunotherapi
led
viral
propag
blunt
infect
pup
also
induct
longlast
protect
humor
immun
particularli
interest
observ
one
consid
frcase
model
reminisc
perinat
infect
hiv
includ
breastfeedingmedi
mothertochild
viru
transmiss
evid
induct
vaccinelik
effect
antivir
mab
come
studi
sever
preclin
model
human
viral
infect
hivinfect
patient
mous
model
rsv
infect
administr
neutral
mab
direct
viru
attach
protein
g
induc
shift
adapt
immun
respons
lead
sustain
enhanc
humor
tcell
howev
effect
fcdepend
rather
due
abil
therapeut
mab
counteract
intrins
immunosuppress
activ
rsv
g
protein
mabdriven
enhanc
humor
respons
also
report
two
preclin
model
henipaviru
infect
african
green
recoveri
hendra
nipah
virusinduc
diseas
correl
develop
host
antibodi
respons
consequ
administr
highli
neutral
mab
hendra
nipah
viru
crossreact
mab
current
consid
human
use
final
antihiv
antibodi
modul
immun
respons
infect
organ
effect
initi
report
sever
nonhuman
primat
model
hiv
infect
observ
infect
human
macaqu
infect
differ
strain
simian
immunodefici
viru
siv
simian
hiv
shiv
chimer
viru
hiv
env
substitut
siv
allow
assess
antivir
effect
antihiv
antibodi
follow
differ
protocol
experi
show
administr
highli
neutral
antibodi
either
mab
polyclon
ig
enhanc
humor
cellular
antivir
immun
respons
treat
interestingli
recent
clinic
data
describ
elicit
host
humor
respons
virem
subject
upon
singl
inject
potent
antihiv
howev
mechan
lead
stimul
antivir
immun
respons
preclin
model
hiv
infect
infect
patient
remain
uncharacter
moreov
unknown
whether
antivir
respons
genuin
protect
vaccinelik
effect
case
import
observ
open
new
avenu
improv
mabbas
antivir
hiv
therapi
moreov
vivo
activ
bnab
includ
viral
load
control
recent
shown
crucial
depend
fc
effector
import
issu
identifi
interact
involv
induct
vaccinelik
effect
antivir
mab
understand
mechan
underli
enhanc
antivir
respons
ic
sever
vitro
studi
address
whether
antibodymedi
viral
uptak
dc
could
lead
stronger
activ
cell
develop
stronger
virusspecif
tcell
respons
fcdepend
manner
increas
cellular
immun
respons
report
differ
infecti
set
use
ic
made
differ
type
antigen
includ
recombin
viral
protein
whole
virion
well
infect
cell
tabl
concern
ic
made
viral
protein
sever
report
shown
ic
made
antihbv
mab
hepat
b
surfac
antigen
hbsag
affect
dc
function
enhanc
tcell
respons
hbsagantihbv
ic
significantli
increas
uptak
immunocomplex
hbsag
antigen
augment
vitro
prolifer
virusspecif
cell
product
interferon
ifn
moreov
dc
hbvinfect
patient
incub
hbsagantihbv
ic
show
higher
express
major
histocompat
complex
mhc
ii
molecul
higher
product
interleukin
il
icload
dc
also
enhanc
product
cocultur
interestingli
therapeut
efficaci
hbsagantihbv
ic
test
clinic
trial
see
hbvinfect
patient
encourag
recent
experi
aim
visual
immunopotenti
hbsagantihbv
ic
see
livecel
imag
reveal
ic
intern
via
apc
subsequ
transport
earli
late
endosom
lysosom
coloc
mhci
mhcii
consist
latter
observ
administr
dc
load
hbsagantihbv
ic
mice
increas
number
tumor
necrosi
cell
similarli
siv
infect
set
incub
apc
ic
made
recombin
fulllength
gag
protein
igg
increas
siv
capsid
crosspresent
capsid
crosspresent
depend
uptak
immunocomplex
siv
capsid
protein
requir
proteasom
endosom
degrad
gener
stronger
gagspecif
tcell
mechanist
standpoint
studi
indic
antivir
antibodi
might
enhanc
prime
expans
virusspecif
cell
promot
secret
key
cytokin
facilit
uptak
crosspresent
viral
ag
dc
immunecomplex
whole
virion
also
shown
affect
function
activ
dc
stimul
dc
ic
compos
siv
virion
highli
neutral
sivhyperimmun
sera
svig
led
increas
virusspecif
tcell
respons
fcdepend
contrast
dc
stimul
ic
made
polyclon
igg
pool
hivinfect
subject
show
weak
hivspecif
ctlstimul
activ
suggest
opson
igg
might
associ
decreas
ctlstimulatori
dc
howev
igg
isotyp
display
equival
effector
function
therefor
undefin
natur
antibodi
term
predomin
isotyp
neutral
potenti
use
form
hivic
experi
might
explain
observ
whether
hivic
made
highli
neutral
antihiv
mab
specif
igg
isotyp
might
induc
stronger
tcell
respons
import
issu
deserv
investig
figur
moreov
natur
viral
determin
present
ic
might
also
crucial
stimul
antivir
respons
interestingli
mention
mous
frcase
infect
model
ic
made
neutral
mab
infect
cell
made
virion
effici
induc
strong
gagspecif
tcell
respons
high
cytotox
observ
show
viral
cellular
ic
trigger
differ
immunolog
outcom
case
frcase
explain
fact
frcasegagl
ctl
immunodomin
epitop
best
poorli
incorpor
virion
taken
togeth
data
indic
uptak
cellular
ic
might
allow
present
broader
viral
antigen
repertoir
lead
stronger
effect
immun
figur
ic
form
endogen
antibodi
gener
viral
infect
mice
shown
influenc
antivir
cellular
immun
respons
sever
model
tabl
notabl
highli
neutral
humor
respons
gener
frcase
retroviru
mabtreatedinfect
mice
demonstr
limit
viral
propag
enhanc
memori
cellular
respons
long
disappear
therapeut
mab
occur
within
two
week
post
administr
reflect
natur
igg
lifespan
vivo
icmedi
activ
dc
upon
bind
key
similarli
influenza
viru
infect
model
ic
form
endogen
antivir
antibodi
promot
sustain
antigen
present
dc
result
stronger
tcell
interestingli
prolong
antigen
present
dc
depend
virusspecif
isotypeswitch
antibodi
facilit
captur
crosspresent
viral
antigen
dc
addit
serum
antibodi
affect
virusspecif
tcell
balanc
fcdepend
manner
rsv
enhanc
ratio
rsvneutral
nonneutr
antibodi
profoundli
enhanc
tcell
respons
murin
lymphocyt
choriomening
viru
lcmv
infect
model
endogen
virusspecif
antibodi
could
stimul
innat
immun
therebi
posit
affect
induct
mainten
virusspecif
tcell
respons
notabl
antilcmv
antibodi
limit
viral
replic
peripher
organ
allow
replic
viru
margin
zone
spleen
promot
tcell
interestingli
antilcmv
antibodi
also
report
essenti
longterm
mainten
memori
ctl
respons
infect
observ
togeth
vitro
studi
describ
demonstr
virusspecif
antibodi
promot
acquisit
process
present
antigen
subsequ
instrument
prime
tcell
respons
program
function
memori
fcdepend
manner
strengthen
concept
antivir
antibodi
regul
qualiti
function
antivir
tcell
respons
format
ic
moreov
also
provid
rational
develop
novel
icbas
therapeut
vaccin
strategi
ic
test
vaccin
augment
protect
immun
respons
differ
anim
model
hbv
infect
duck
ic
made
duck
hbsag
rabbit
antiduck
hbsag
dhbsagantidhb
use
immunogen
form
solid
complex
smaa
smaa
contain
kill
staphylococcu
aureu
solid
matrix
mabopson
initi
shown
induc
humor
ctl
respons
paramyxoviru
simian
viru
immun
immun
hbvinfect
duck
smaabas
dhbsagantidhb
ic
led
viral
clearanc
infect
duck
notabl
administr
dhbsagantidhb
ic
lack
staphylococcu
aureu
show
decreas
immun
effici
suggest
bacteriabas
solid
matrix
function
ic
also
test
therapeut
vaccin
hbv
infect
balbc
mice
immun
hbsagantihbv
ic
produc
increas
level
virusspecif
moreov
administ
hbsagantihbv
ic
balbc
mice
via
intranas
inhal
induc
mucos
system
immun
respons
administ
adjuv
cholera
toxin
oligodeoxynucleotid
contain
immunostimulatori
cpg
motif
cpg
observ
use
hbsag
addit
administr
hbsagantihbv
ic
hbsagposit
transgen
mice
decreas
serum
hbsag
level
induc
stronger
ctl
respons
hbsag
notabl
coadministr
ic
plasmid
code
hbsag
increas
antivir
immun
respons
induc
ic
indic
adjuv
effect
dna
set
similar
effect
also
report
woodchuck
model
hbv
infect
immun
woodchuck
hepat
viru
whv
infect
anim
whv
surfac
antigenantiwhv
antibodi
ic
combin
dna
vaccin
result
higher
reduct
viral
load
antigenemia
rel
ic
interestingli
whvinfect
anim
pretreat
lamivudin
potent
hbv
antivir
drug
abl
enhanc
tcell
respons
chronic
hbvinfect
patient
icdna
immun
suggest
combin
strategi
consid
treat
chronic
hbv
infect
figur
enhanc
antivir
immun
respons
ic
vitro
preclin
model
hbv
infect
pave
way
develop
icbas
therapeut
vaccin
strategi
chronic
viral
hepat
b
infect
therapeut
vaccin
compos
yeastderiv
recombin
hbsagantihbv
immunogen
complex
yic
test
seri
clinic
trial
vaccin
approach
initi
shown
safe
induc
higher
titer
hbsag
antibodi
well
increas
serum
level
phase
importantli
subpopul
chronic
viral
hepat
b
patient
show
decreas
serum
hbv
viral
load
hbsag
level
togeth
increas
antihbsag
antibodi
titer
subsequ
phase
ii
mechanist
standpoint
recent
data
show
administr
yicload
dc
mice
increas
tcell
suggest
improv
immun
respons
induc
yic
might
account
antivir
effect
observ
fraction
patient
attempt
enhanc
immunogen
potenti
yicbas
vaccin
phase
iii
trial
test
therapeut
effect
higher
number
ic
dose
unfortun
overstimul
yic
decreas
vaccin
effici
due
host
immun
suggest
vaccin
protocol
must
optim
must
take
account
natur
dose
ic
well
paramet
rout
administr
type
adjuv
immunolog
statu
patient
achiev
effici
protect
immun
figur
studi
immun
healthi
volunt
hiv
author
found
compar
free
antigen
recal
immun
ic
induc
stronger
tcell
respons
uncharacter
mechan
report
also
describ
alter
antihiv
respons
particular
immun
immunocompet
mice
ic
contain
recombin
env
glycoprotein
mab
mab
direct
site
induc
higher
virusneutr
antibodi
respons
rel
free
antigen
describ
humor
respons
increas
upon
coadministr
ic
monophosphoryl
lipidadimethyldioctadecylammonium
adjuv
notabl
interact
site
mab
induc
conform
chang
latter
lead
enhanc
antigen
immunogen
neutral
epitop
local
observ
highlight
abil
antibodi
induc
antigen
alter
specif
epitop
upon
ic
format
interestingli
improv
immunogen
loop
obtain
ic
gener
mutant
lack
sitespecif
nlink
taken
togeth
observ
suggest
abil
ic
stimul
induct
neutral
antibodi
dictat
natur
antigen
well
specif
affin
mab
util
result
also
indic
potenti
contribut
fabmedi
activ
enhanc
antivir
humor
respons
ic
tsouchnika
et
investig
influenc
immun
ic
specif
antibodi
respons
use
e
protein
tickborn
enceph
viru
immunogen
mice
immun
dimer
solubl
form
e
se
alon
complex
mab
specif
three
domain
e
antibodi
respons
induc
ic
compar
observ
immun
se
alon
unexpectedli
immun
ic
chang
extent
overal
antibodi
respons
immun
mice
howev
substanti
differ
antibodi
respons
observ
differ
ic
differ
like
reflect
epitopeshield
phenomenon
antibodymedi
structur
chang
led
dissoci
se
dimer
thu
phenomena
profoundli
influenc
fine
specif
antibodi
respons
immunogen
must
consid
icbas
vaccin
strategi
mention
serum
antirsv
antibodi
affect
virusspecif
tcell
basi
kruijsen
et
test
whether
ic
made
commerci
rsvneutral
mab
palivizumab
could
influenc
adapt
immun
respons
prime
intranas
administr
substanti
antirsv
tcell
prime
bcell
respons
observ
mice
receiv
rsvic
result
predomin
tcell
respons
antibodi
respons
importantli
ic
also
prime
antirsv
cell
data
import
implic
prophylaxi
treatment
pediatr
rsv
infect
nevertheless
interact
ic
neonat
versu
adult
innat
adapt
immun
system
still
need
investig
mous
studi
reveal
potenti
antibodyinduc
neonat
autoimmun
certain
cours
viral
infect
format
ic
compos
viral
determin
result
host
humor
respons
potenti
produc
deleteri
effect
persist
ic
form
varieti
chronic
viral
infect
may
lead
unregul
protract
signal
may
lead
immun
dysfunct
instead
stimul
antivir
immun
respons
regard
high
level
ic
form
lcmv
infect
interfer
endogen
form
ic
shown
outcompet
effector
function
exogen
administ
therapeut
mab
particular
bind
express
immun
cell
persist
endogen
ic
also
link
dysfunct
bcell
respons
hiv
infect
includ
suppress
antivir
iga
respons
impair
product
neutral
antibodi
review
moir
et
composit
ic
might
also
neg
affect
effici
antivir
immun
respons
instanc
composit
ic
shown
dynam
throughout
cours
hiv
infect
due
chang
antibodi
specif
virion
level
notabl
circul
ic
initi
compris
antibodi
opson
infecti
noninfecti
virion
result
decreas
avail
antibodi
abl
blunt
viral
propag
phenomenon
probabl
contribut
reduc
effici
antibodi
gener
acut
chang
circul
ic
also
report
hcv
infect
level
circul
ic
low
acut
infect
patient
wherea
chronic
infect
individu
show
high
proport
immunocomplex
hcv
rais
possibl
ic
may
role
pathogenesi
hcv
name
liver
moreov
format
ic
nonneutr
antibodi
may
also
lead
antibodydepend
enhanc
viral
infect
cell
happen
sever
viral
infect
includ
dengu
along
line
bind
ic
monocytesmacrophag
paradox
suppress
innat
immun
induc
product
bia
respons
toward
turn
lead
increas
infecti
output
infect
cell
via
intrins
antibodydepend
final
ic
also
report
role
increas
viral
load
context
gene
transferbas
vaccin
strategi
step
vaccin
trial
evalu
replicationdefect
adenoviru
type
vector
vaccin
ic
form
preexist
antibodi
improv
environ
replic
cell
may
due
icdriven
activ
axi
induc
activ
cell
lead
permiss
environ
infect
environ
probabl
explain
increas
propag
infect
among
adenoviru
type
vaccin
sever
approach
consid
enhanc
immunomodulatori
potenti
antivir
mab
alon
form
ic
particular
combin
neutral
mab
icbas
vaccin
strategi
therapi
first
possibl
would
consist
inhibit
immunosuppress
mechan
infect
individu
either
deplet
treg
respons
suggest
nasser
et
target
immun
checkpoint
latter
strategi
alreadi
led
improv
immun
respons
viral
infect
addit
combin
antivir
mab
differ
immunostimulatori
agent
also
envisag
primari
structur
glycosyl
pattern
fc
fragment
essenti
antibodi
effector
function
due
impact
engag
type
type
ii
fcr
famili
fc
engin
might
also
repres
anoth
approach
improv
direct
antivir
effect
also
induc
stronger
vaccinelik
effect
regard
identif
main
fcr
fcrmediat
mechan
involv
enhanc
antivir
immun
respons
utmost
import
take
account
variou
igg
isotyp
display
differ
effector
function
interact
differ
care
select
antivir
mab
subclass
also
crucial
enhanc
antivir
immun
respons
final
polymorph
alreadi
associ
differ
viral
diseas
progress
therapeut
effici
anticanc
mab
import
evalu
extent
polymorph
affect
vaccinelik
effect
induc
mabbas
antivir
immunotherapi
therapeut
potenti
antivir
mab
wide
accept
use
antivir
drug
increasingli
consider
divers
biolog
activ
mab
lead
direct
control
viral
propag
modul
antivir
immun
provid
novel
rational
use
divers
prophylact
therapeut
approach
improv
humor
cellular
respons
achiev
administr
mab
either
free
form
immunogen
ic
offer
new
therapeut
option
challeng
improv
understand
ic
convert
mabbas
immunotherapi
passiv
activ
exploit
underli
mechan
convers
crucial
reach
goal
use
antivir
mab
induc
longlast
protect
immun
lifethreaten
viral
infect
